Through the close cooperation of multidisciplinary team, not only do the patients with resectable LABC have an opportunity to be converted from mastectomy to BCS candidates after NACT, but the women with early-stage triple-negative or HER2 - positive BC who are currently candidates for NACT are safe to receive BCS. This evidence concerns the gene ERBB2 and breast cancer.